Arthritis Therapeutics Market To 2018 - Novel Oral JAK Inhibitors And Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95
Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96
Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104
Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106
Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107 Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109 Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110 Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111 Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112 Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132 Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133 Figure 41: GBI Research Market Forecasting Model 139 Companies Mentioned Roche Johnson & Johnson Pfizer Abbott Laboratories Bristol- Myers Squibb Amgen To order this report: Therapy Industry: Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications __________________________ Contact Clare: clare@reportlinker.com US:(339) 368 6001Intl:+1 339 368 6001 SOURCE Reportlinker
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
